论文部分内容阅读
本研究对甘草酸二铵肠溶胶囊防治抗结核药物对肝功能损害临床疗效的前瞻性进行分析。统计分析2013年1月至2014年12月期间的180例结核病患者的临床资料。在本次研究中,观察组患者治疗2周、1个月和2个月后的肝功能损伤发生率为1.11%、5.56%和13.33%,对照组的发生率为7.78%、17.78%和30.00%(p<0.05)。观察组与对照组患者治疗后的肝功能指标(谷丙转氨酶,谷草转氨酶,总胆红素)与治疗前比较有显著差异(p<0.05)。且治疗后的观察组与对照组患者的肝功能指标对比分析,有显著差异(p<0.05)。通过相关分析表明抗结核疾病的治疗中,使用甘草酸二铵肠溶胶囊治疗,可以显著的降低对患者肝功能产生的损伤,促进结核疾病的顺利进行,并提高治疗成功率。
The study of diammonium glycyrrhizinate enteric-coated capsules prevention and treatment of anti-TB drugs on the clinical efficacy of liver damage were prospective analysis. The clinical data of 180 tuberculosis patients from January 2013 to December 2014 were statistically analyzed. In this study, the incidence of hepatic injury in observation group was 1.11%, 5.56% and 13.33% at 2 weeks, 1 month and 2 months after treatment. The incidence of control group was 7.78%, 17.78% and 30.00 % (p <0.05). The liver function indexes (alanine aminotransferase, aspartate aminotransferase, total bilirubin) after treatment in observation group and control group were significantly different from those before treatment (p <0.05). There was significant difference (P <0.05) between the observation group and the control group after liver function comparison. Correlation analysis showed that anti-tuberculosis treatment with diammonium glycyrrhizinate enteric-coated capsules could significantly reduce the damage to liver function, promote the smooth progress of tuberculosis and improve the success rate of treatment.